521 related articles for article (PubMed ID: 16773706)
21. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathologic features of drug-induced vanishing bile duct syndrome].
Ye LH; Wang CK; Zhang HC; Liu ZQ; Zheng HW
Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):317-320. PubMed ID: 28494557
[TBL] [Abstract][Full Text] [Related]
23. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
24. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
25. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
28. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis.
Sakisaka S; Koga H; Sasatomi K; Ohishi M; Kawaguchi T; Harada M; Taniguchi E; Uchimura Y; Ueno T; Sata M; Tanikawa K
Liver; 2000 Feb; 20(1):78-87. PubMed ID: 10726964
[TBL] [Abstract][Full Text] [Related]
29. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
Trauner M; Graziadei IW
Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
[TBL] [Abstract][Full Text] [Related]
30. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
32. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
[TBL] [Abstract][Full Text] [Related]
33. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid in the treatment of AIDS-associated cholangiopathy.
Castiella A; Iribarren JA; López P; Arrizabalaga J; Rodríguez F; von Wichmann MA; Arenas JI
Am J Med; 1997 Aug; 103(2):170-1. PubMed ID: 9274905
[No Abstract] [Full Text] [Related]
35. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
36. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
37. Drug-induced vanishing bile duct syndrome: response to ursodiol.
O'Brien CB; Shields DS; Saul SH; Reddy KR
Am J Gastroenterol; 1996 Jul; 91(7):1456-7. PubMed ID: 8678017
[No Abstract] [Full Text] [Related]
38. Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.
Bakhit M; McCarty TR; Park S; Njei B; Cho M; Karagozian R; Liapakis A
World J Gastroenterol; 2017 Jan; 23(2):366-372. PubMed ID: 28127210
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
40. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
